1 / 3

Antibody Drug Conjugates Market: Shows Increasing Demand To Be Observed In The Coming Decade

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer<br>

rushi12
Download Presentation

Antibody Drug Conjugates Market: Shows Increasing Demand To Be Observed In The Coming Decade

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antibody Drug Conjugates Market - Size, Share, Antibody Drug Conjugates Market - Size, Share, Growth, Outlook, and Opportunity Analysis, Growth, Outlook, and Opportunity Analysis, 2018-2026 2018-2026 Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/181 By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market. Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting

  2. for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins. Report includes chapters which deeply display the following deliverable about industry : • Antibody Drug Conjugates Market Research Objective and Assumption • Antibody Drug Conjugates Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Antibody Drug Conjugates Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Antibody Drug Conjugates Market, By Regions • Antibody Drug Conjugates Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Antibody Drug Conjugates Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Antibody Drug Conjugates Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Antibody Drug Conjugates Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Inquire Here Before Purchase:

  3. https://www.coherentmarketinsights.com/insight/talk-to-analyst/181 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related